NCT06005740

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: TORL Biotherapeutics, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).

Conditions

• Advanced Solid Tumor
• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	TORL-4-500	antibody drug conjugate

Timeline

• Start date: 2023-12-04
• Primary completion: 2025-10-31
• Completion: 2026-10-31
• First posted: 2023-08-22
• Last updated: 2025-03-04

Locations

10 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study